Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kumetrix Inc.

This article was originally published in Start Up

Executive Summary

Failure to monitor blood glucose regularly to control sugar levels is the leading cause of health complications in diabetics. The primary reason for this failure is the pain involved in the most common method of monitoring -- pricking a fingertip with a lancet to draw a blood sample. While 95% of the $3 billion market for blood glucose monitoring products is held by just four companies, there has been a surge of entrants into the field in recent years. These new players hope to improve patient compliance by developing noninvasive and painless methods for sampling blood or interstitial fluids through the use of implants, spectroscopy, ultrasound, and other innovative techniques. The failure rate among these start-ups is high. And despite the promise of many of these methods, industry analysts agree that an easy to use, cost-effective and reliable alternative to the finger prick is still years away. Kumetrix Inc., a San Francisco-based start-up, believes that it can offer an interim solution with its integrated glucose self-test device, designed to mimic the painless bite of the mosquito.

You may also be interested in...

ASTM Developing Standard To Tackle Dried Blood On Steel Devices

ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.

Executives On The Move: CEOs Named At Elevation Oncology, PainReform Ltd

Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma

Viatris Kickstarts Business With Tentative Approval For Pediatric Dolutegravir

The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program. 


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts